Intellia (NTLA) Begins Dosing in Phase III ATTR Amyloidosis Study [Yahoo! Finance]
Intellia Therapeutics, Inc. (NTLA)
Last intellia therapeutics, inc. earnings: 2/27 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.intelliatx.com/investor-overview
Company Research
Source: Yahoo! Finance
vivo genome-editing candidate, NTLA-2001, for the treatment of transthyretin (ATTR) amyloidosis, a rare and fatal disease that can lead to heart failure. The double-blind and placebo-controlled MAGNITUDE study will evaluate the safety and efficacy of NTLA-2001 in patients with ATTR amyloidosis with cardiomyopathy. The company started dosing in the phase III MAGNITUDE study after interim data from a phase I study showed that treatment with a single dose of NTLA-2001 led to deep and durable reductions of the TTR protein responsible for the disease. If the data from the MAGNITUDE study is found to be positive, it will enable regulatory filings for the drug across the world. Shares of Intellia have plunged 28.5% in the past year compared with the industry's decline of 8.1%. Image Source: Zacks Investment Research In October 2023, the FDA cleared NTLA's investigational new drug application to move NTLA-2001 into clinical studies for the treatment of ATTR amyloidosis with cardio
Show less
Read more
Impact Snapshot
Event Time:
NTLA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NTLA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NTLA alerts
High impacting Intellia Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
NTLA
News
- Intellia (NTLA) to Report Q1 Earnings: What's in the Cards? [Yahoo! Finance]Yahoo! Finance
- Earnings Preview: Intellia Therapeutics, Inc. (NTLA) Q1 Earnings Expected to Decline [Yahoo! Finance]Yahoo! Finance
- Intellia Therapeutics, Inc. (NASDAQ: NTLA) had its "neutral" rating re-affirmed by analysts at Wedbush. They now have a $29.00 price target on the stock.MarketBeat
- 2 Stocks Down 30% to Buy Right Now [Yahoo! Finance]Yahoo! Finance
- Intellia Therapeutics (NASDAQ:NTLA shareholders incur further losses as stock declines 9.9% this week, taking three-year losses to 65% [Yahoo! Finance]Yahoo! Finance
NTLA
Earnings
- 2/22/24 - Beat
NTLA
Sec Filings
- 4/22/24 - Form 3
- 4/16/24 - Form PRE
- 4/15/24 - Form 8-K
- NTLA's page on the SEC website